Research programme: intranasal iodine - BioCide/Symbollon

Drug Profile

Research programme: intranasal iodine - BioCide/Symbollon

Alternative Names: Nasodine

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Symbollon Pharmaceuticals
  • Developer BioCide Pharma; Symbollon Pharmaceuticals
  • Class Disinfectants; Halogens; Oxidants
  • Mechanism of Action Cell membrane modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Bacterial infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections(Prevention) in USA (Inhalation)
  • 21 Feb 2011 Preclinical development is ongoing in USA
  • 15 Sep 2009 Pharmacodynamics and Adverse event data from preclinical trials in Bacterial infections presented at the Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top